Therapeutic uses of smad protein inhibitors: Selective inhibition of specific TGF-β activities

IDrugs

Volumn 2, Issue 9, 1999, Pages 907-914

  Laping, Nicholas J ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACTIVIN; ACTIVIN RECEPTOR; BLEOMYCIN; BONE MORPHOGENETIC PROTEIN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ALZHEIMER DISEASE; CANCER; DNA BINDING; ENZYME INHIBITION; FIBROSIS; HUMAN; KIDNEY FIBROSIS; LUNG FIBROSIS; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; RESTENOSIS; REVIEW; SIGNAL TRANSDUCTION; WOUND HEALING;

EID: 0032857422     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Roberts AB, Anzano MA, Lamb LC, Smith JM, Sporn MB: New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. Proc Natl Acad Sei USA (1981) 78:5339-5343.
2. Heldin CH, Miyazorio K, ten Dijke P: TGF-JJ signaling from cell membrane to nucleus through SMAD proteins. Nature (1997)390:465-471.
3. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J: Mechanism of activation of the TGF-β receptor. Nature (1994)370:341-347.
4. Wrana JL: TGF-β receptors and signaling mechanisms. Miner Electrolyte Metab (1998) 24:120-130.
5. Attisano L, Wrana JL: Signal transduction by members of the transforming growth factor-β superfamily. Cytokine Growth Factor Rev (1996) 7:327-339.
6. Massague J, Weis-Garcia F: Serine/threonine kinase receptors: mediators of transforming growth factor β family signals. Cancer Surv (1996) 27:41-64.
7. Chen RH, Ebner R, Derynck R: Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-β activities. Science (1993) 260:1335-1338.
8. Kim IY, Zelner DJ, Lee C: The conventional transforming growth factor-β (TGF-β) receptor type I is not required for TGF-β 1 signaling in a human prostate cancer cell line, LNCaP. Exp Cell Res (1998) 241:151-160.
9. Raftery LA, Twombly V, Wharton K, Gelbart WM: Genetic screens to identify elements of the decapentaplegic signaling pathway in Drosophila. Proc Nail Acad Sei USA (1995)139:241-254.
10. Sekelsky JJ, Newfeld SJ, Raftery LA, Chartoff EH, Gelbart WM: Genetic characterization and cloning of mothers against dpp, a gene required for decapentaplegic function in Drosophila melanogaster. Proc Natl Acad Sei USA (1995) 139:1347-1358.
11. Lo RS, Chen YG, Shi Y. Pavletich NP. Massague J: The L3 loop: a structural motif determining specific interactions between SMAD proteins and TGF-β receptors. EMBO J (1998)17:996-1005.
12. Hoodless PA, Haerry T, Abdollah S, Stapleton M, Oconnor MB, Attisano L, Wrana JL: Madrl, a mad-related protein that functions in BMP-2 signaling pathways. Cell (1996) 85:489500.
13. Yamamoto N, Akiyama S, Katagiri T, Namiki M, Kurakawa T, Suda T: Smad1 and smadS act downstream of intracellular signalings of BMP-2 that inhibits myogenic differentiation and induces osteoblast differentiation in C2C12 myoblasts. Biochem Biophys Res Commun (1997) 238:574580.
14. Kretzschmar M, Liu F, Hata A, Doody J, Massague J: The TGF-β family mediator smadl is phosphorylated directly and activated functionally by the bmp receptor kinase. Genes Dev (1997) 11:984-995.
15. Macias-Silva M, Hoodless PA, Tang SJ, Buchwald M, Wrana JL: Specific activation of smadl signaling pathways by the BMP-7 type I receptor, ALK2. JBiol Chem (1998) 273:2562825636.
16. Nakao A, Imamura T, Souchelnylskyi S, Kawabata M, Ishisaki A, Oeda E, Tamaki K, Hanai J, Heldin CH, Miyazono K, ten Dijke P: TGF-β receptor-mediated signaling through Smad2, Smad3 and Smad4. EMBO J 1(997) 16:5353-5362.
17. Zhang Y, Feng X, We R, Derynck R: Receptor-associated Mad homologues synergize as effectors of the TGF-β response. Nature (1996) 383:168-172.
18. Lagna G, Hata A, Hemmati-Brivanlou A, Massague J: Partnership between DPC4 and SMAD proteins in TGF-β signaling pathways. Nature (1996) 383:832-836.
19. Zhang Y, Musci T, Derynck R: The tumor suppressor Smad4/DPC 4 as a central mediator of Smad function. Curr Biol (1997) 7:270-276.
20. Imamura T, Takase M, Nishihara A, Oeda E, Hanai J, Kawabata M, Miyazono K: Smad6 inhibits signalling by the TGF-β superfamily. Nature (1997) 389:622-626.
21. Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R, Itoh S, Kawabata M, Heldin NE, Heldin CH, ten Dijke P: Identification of Smad7, a TGF-β-inducible antagonist of TGF-β signaling. Nature (1997) 389:631-635.
22. Yingling JM, Datto MB, Wong C. Frederick JP, Uberati NT, Wang XF: Tumor suppressor Smad4 is a transforming growth factor-β inducible DNA binding protein. Mol Cell Biol (1997)17:7019-7028.
23. Abdollah S, Macias-Silva M, Tsukazaki T, Hayashi H, Attisano L, Wrana JL: TβRI phosphorylation of Smad2 on Ser and Ser is required for Smad2-Smad4 complex formation and signaling. J Biol Chem (1997) 272:27678-27685.
24. Souchelnytskyi S, Tamaki K. Engstrom U, Wemstedt C, ten Dijke P, Heldin CH: Phosphorylation of Ser and Ser in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-β signaling. J Biol Chem (1997) 272:28107-28115.
25. Macias-Silva M, Abdollah S, Hoodless PA, Pirone R, Attisano L, Wrana JL: MADR2 is a substrate of the TGF-β receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell (1996) 87:1215-1224.
26. Eyers PA, Craxton M, Morrice N, Cohen P, Goedert M: : Conversion of SB-203580-insensitive MAP kinase family , members to drug-sensitive forms by a single amino-acid substitution. Chem Biol (1998) 5:321-328.
27. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM: Direct binding of Smad3 and Smad4 to critical TGF-βinducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EM BO J (1998) 17:30913100.
28. Jonk LJ, Itoh S, Heldin CH, ten Dijke P, Kruijer W: Identification and functional characterization of a Smad binding element (SBE) in the JunB promoter that acts as a transforming growth factor-β, activin, and bone morphogenetic protein-inducible enhancer. J Biol Chem (1998)273:21145-21152.
29. Song CZ, Siok TE, Gelehrter TD: Smad4/DPC4 and smad3 mediate transforming growth factor-beta (TGF-β) signaling through direct binding to a novel TGF-β-responsive element in the human plasminogen activator inhibitor-1 promoter. J Biol Chem (1998) 273:29287-29290.
30. Zhang Y, Feng XH, Derynck R: Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-β-induced transcription. Nature (1998) 394:909-913.
31. Li JM, Nichols MA, Chandrasekharan S, Xiong Y, Wang XF: Transforming growth factor-β activates the promoter of cyclin-dependent kinase inhibitor p15INK4B through an Sp1 consensus site. J Biol Chem (1995) 270:26750-26753.
32. Datto MB, U Y, Panus JF, Howe DJ. Xiong Y, Wang XF: Transforming growth factor-β induces the cyclindependent kinase inhibitor p21 through a p53-independent mechanism. Proc NatlAcad Sei USA (1995) 92:5545-5549.
33. Zawel L, Dai JL, Buckhaults P, Zhou S, Kinzler KW, Vogelstein B, Kem SE: Human Smad3 and Smad4 are sequencespecific transcription activators. Mol Cell (1998) 1:611-617.
34. Shi Y, Wang YF, Jayaraman L, Yang H, Massague J, Pavletich NP: Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-β signaling. Cell (1998)94:585-594.
35. Border WA, Noble NA: Transforming growth factor-β in tissue fibrosis. New Engl JMed (1994) 10:1286-1292.
36. Yoshioka K, Takemura T, Murakami K, Okada M, Hino S, Miyamoto H, Maki S: Transforming growth factor-β protein and mRNA in glomeruli in normal and diseased human kidneys. Lab Invest (1993) 68:154-163.
37. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA: Expression of transforming growth factor-β is elevated in human and experimental diabetic nephropathy. Proc Nat! AcadSci USA (1993) 90:1814-1818.
38. Castilla A: Transforming growth factors betal and alpha in chronic liver disease: effects of Interferon a therapy. New Engl J Med (1991 ) 324:933-940.
39. Nagy P: Immunohistochemical detection of transforming growth factor-β1 in fibrotic liver diseases. Hepatology (1991) 14:269-273.
40. Anscher MS: Transforming growth factor-β as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. New Engl J Mecf (1993) 328:1592-1598.
41. Broekelmann TJ: Transforming growth factor-β1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc NatlAcad Sei USA (1991) 88:66426646.
42. Kulozik M: Co-localization of transforming growth factor-β2 with cc-1(l) procollagen mRNA in tissue sections of patients with systemic sclerosis. J Clin Invest (1990) 86:917-922.
43. Nikol S: Expression of transforming growth factor-β1 is increased in human vascular restenosis lesions. J Clin Invest (1992) 90:1582-1592.
44. Lafyatis R: Transforming growth factor-β production by synovial tissues from rheumatoid patients and streptococcal cell wall arthritic rats: studies on secretion by synovial fibroblast-like cells and immunohistologic localization. Jlmmunol (1989) 143:1142-1148.
45. Usui T, Takase M, Kaji Y, Suzuki K, Ishida K, Tsuru T, Miyata K, Kawabata M, Yamashita H: Extracellular matrix production regulation by TGF-β in corneal endothelial cells. Invest Ophthalmol Vis Sei (1998) 39:1981-1989.
46. Bitzer M, Sterzel RB, Bottinger EP: Transforming growth factor-β in renal disease. Kidney Blood Press Res (1998) 21:1-12.
47. Border WA, Noble NA: Evidence that TGF-β should be a therapeutic target in diabetic nephropathy. Kidney Int (1998)54:1390-1391.
48. Border WA, Noble NA, Ketteier M: TGF-β: a cytokine mediator of glomerulosclerosis and a target for therapeutic intervention. Kidney Int Suppl (1995) 49:859-61 :S59-S61.
49. Nakamura T, Miller D, Ruoslahti E, Border WA: Production of extracellular matrix by glomerular epithelial cells Is regulated by transforming growth factor-β1. Kidney Int (1992)41:1213-1221.
50. Ziyadeh FN, Sharma K, Ericksen M, Wolf G: Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-β. J Clin Invest (1994) 93:536-542.
51. Tomooka S, Border WA, Marshall BC, Noble NA: Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int (1992) 42:1462-1469.
52. Border WA, Okuda S, Languino LR, Spom MB, Ruoslahti E: Suppression of experimental glomerulonephritis by antiserum against transforming growth factor-β1. Nature (1990)346:371-374.
53. Sharma K, Jin Y, Quo J, Ziyadeh FN: Neutralization of TGF-β by anti-TGF-β antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZInduced diabetic mice. Diabetes (1996) 45:522-530.
54. Imai E, Isaka Y. Fujiwara Y. Kaneda Y, Kamada T, Ueda N: Introduction of a foreign gene into the kidney in vivo: development of glomerulosclerosis by the transaction of genes for PDGF and TGF-β. Contrib Nephrol (1994) 107:205215.
55. Isaka Y, Fujiwara Y. Ueda N, Kaneda Y, Kamada T, Imai E: Glomerulosclerosis induced by in vivo transfection of transforming growth factor-β or platelet-derived growth factor gene into the rat kidney. J Clin Invest (1993) 92:2597-2601.
56. Kopp JB, Factor VM, Mozes M, Nagy P, Sanderson N, Bottinger EP, Klotman PE, Thorgeirsson SS: Transgenlc mice with increased plasma levels of TGF-β1 develop progressive renal disease. Lablnvest(1996) 74:991-1003.
57. Anderson K, Kelly M, Sauermelcri C, Willette R, Ohlstein E: Selective upregulation of type I TGF-β-receptor expression in response to vascular injury. Circulation (1997) 96 Suppl 1:616.
58. Saltis J, Agrotis A, Bobik A: Regulation and interactions of transforming growth factor-β with cardiovascular cells: implications for development and disease. Clin Exp Pharmacol Physiol (1996) 23:193-200.
59. Anderson K, Brawner M, Nichols A: Transforming growth factor-β in restenosis. In: Coronary Restenosis: From Genetics to Therapeutics. Feuerstein G (Ed), Marcel Dekker Inc. New York (1996):99-127.
60. McCaffrey TA, Consigli S, Du B, Falcone DJ, Sanbom TA, Spokojny AM, Bush HU: Decreased type Il/type l TGF-β receptor ratio in cells derived from human atherosclerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-β1. J Clin Invest (1995) 96:2667-2675.
61. Westergren-Thorsson G: Altered expression of small proteoglycans, collagen and transforming growth factor-β in developing bleomycin-induced pulmonary fibrosis in rats. J Clin Invest (1993) 92:632-637.
62. Giri SN, Hyde DM, Hollinger MA: Effect of antibody to transforming growth factor-β on bleomycin induced accumulation of lung collagen in mice. Thorax (1993) 48:959-966.
63. Khalil N: Regulation of alveolar macrophage transforming growth factor-β secretion by corticqsteroids in bleomycininduced pulmonary inflammation in the rat. J Clin Invest (1993)92:1812-1818.
64. Anscher MS: Plasma transforming growth factor-β1 as a predictor of radiation pneumonitis. Int J Radial Oncol Biol Phys (1998) 41:1029-1035.
65. Shah M: Neutralization of TGF-01 and TGF-β2 or exogenous addition of TGF-β3 to cutaneous rat wounds reduces scarring. J Cell Sei (1995) 108:985-1002.
66. Moller-Pedersen T: Neutralizing antibody to TGF-β modulates stromal fibrosis but not regression of photoablative effect following PRK. Curr Eye Res (1998) 17:736-747.
67. Ernst H: Acceleration of wound healing in gastric ulcers by local injection of neutralizing antibody to transforming growth factor-β1. Gut (1996) 39:172-175.
68. Ishihara A: Transforming growth factor-β1 and β2 promote neurite sprouting and elongation of cultured rat hippocampal neurons. Brain Res (1994) 639:21-25.
69. Martinou JC: Transforming growth factor-β is a potent survival factor for rat embryo motoneurons in culture. Dev Brain Res (1990) 52:175-181.
70. Gross CE, Bednar MM, Howard DB, Sporn MB: Transforming growth factor-βl reduces infarct size after experimental cerebral ischemia in a rabbit model. Stroke (1993) 24:558-562.
71. Finch CE, Laping NJ, Morgan TE, Nichols NR, Pasinetti GM: TGF-β1 is an organizer of responses to neurodegeneration. J Cell Biochem (1993) 53:314-322.
72. Pratt BM, McPherson JM: TGF-β in the central nervous system: potential roles In ischémie injury and neurodegenerative diseases. Cytokine Growth Factor Rev (1997) 8:267-292.
73. Flanders KG, Ren RF, Lippa CF: Transforming growth factor-β in neurodegenerative disease. Prog Neurobiol (1998)54:71-85.
74. Laping NJ, Morgan TE, Nichols NR, Rozovsky I, Young Chan CS, Zarow C, Finch CE: Transforming growth factor-β1 induces neuronal and astrocyte genes: tubulin cc1, glial fibrillary acidic protein and clusterin. Neuroscience (1994) 58:563-572.
75. Baghdassarian D, Toru-Delbauffe D, Gavaret JM, Pierre M: Effects of transforming growth factor-β1 on the extracellular matrix and cytoskeleton of cultured astrocytes. Glia (1993) 7:193-202.
76. Yoshida T, Takeuchi M: Establishment of an astrocyte progenitor cell line: induction of glial fibrillary acidic protein and fibronectin by transforming growth factor-β1. J NeurosciRes (1993) 35:129-137.
77. Laping NJ, Teter B, Nichols NR, Rozovsky I, Finch CE: Glial fibrillary acidic protein: regulation by hormones, cytokines, and growth factors. Brain Pathot (1994) 4:259275.
78. Pasinetti GM, Nichols NR, Tocco G, Morgan T, Laping N, Finch CE: Transforming growth factor-01 and fibronectin messenger RNA in rat brain: responses to injury and celltype localization. Neuroscience (1993) 54:893-907.
79. Wyss-Coray T, Feng L, Masliah E, Ruppe MD, Lee HS, Toggas SM, Rockenstein EM, Mucke L: Increased central nervous system production of extracellular matrix components and development of hydrocephalus In transgenic mice overexpressing transforming growth factor-01. Am J Pathol (1995) 147:53-67.
80. Wyss-Coray T, Masliah E, Mallory M, McConlogue L, JohnsonWood K, Lin C, Mucke L: Amyloidogenic role of cytoklne TGF-β1 in transgenic mice and in Alzheimer's disease. Nature (1997) 389:603-606.
81. Huang SS, Huang FW, Xu J, Chen S, Hsu CY, Huang JS: Amyloid β-peptide possesses a transforming growth factor-β activity. J Biol Chem (1998) 273:27640-27644.
82. Takenoshita S, Tani M, Mogi A, Nagashima M, Nagamachi Y, Bennett WP, Hagiwara K, Harris CC, Yokota J: Mutation analysis of the Smad2 gene in human colon cancers using genomic DMA and intron primers. Carcinogenesis (1998) 19:803-807.
83. Hata A, Shi Y, Massague J: TGF-β signaling and cancer: structural and functional consequences of mutations in smads. Mol Med Today (1998) 4:257-262.
84. Park K, Kim SJ, Bang YJ, Park JG, Kim NK, Roberts AB, Sporn MB: Genetic changes in the transforming growth factor-β (TGF-β) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-β. Proc Nad Acad Sei USA (1994) 91:87728776.
85. Grady WM, Rajput A, Myeroff L, LJU DF. Kwon K, Willis J, Markowitz S: Mutation of the type II transforming growth factor-β receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res (1998) 58:3101 -3104.
86. Aral T, Akiyama Y, Okabe S, Ando M, Endo M, Yuasa Y: Genomic structure of the human SmadS gene and its infrequent alterations in colorectal cancers. Cancer Lett (1998)122:157-163. ..
87. Ananth S. Knebelmann B, Griming W, Dhanabal M, Walz G, Stillman l, Sukhatme V: Transforming growth factor-β1 is a critical growth factor for renal cell carcinoma (RCC) and is a direct target for the von Hippel-Lindau tumor supressor. Journal of the American Society of Nephrology Abstracts (1998)9:433A.